Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Hepion Pharmaceuticals Inc (HEPA)

NASDAQ
Currency in USD
Disclaimer
1.345
+0.025(+1.92%)
Real-time Data

HEPA Comments

below 2 USD is fulfilled. As said previously, Hepion key price was 2, from there it tried to move up in a desperate move but eventually on Apr 19 it went down to 1.3. global market is finally in a down trend and pushing hepion down. Good entry point is 1 due to a second desperate that will appear at such level. Enjoy
2USD fulfilled..unluckily S&P is at record high...which means that a reversal is coming soon and therefore hepion is meant to fall even more..maybe goes from 2 to 3 in a desperate move but global tren will push it to 1. We come back to hepion in july...big month due to presidential elections
Hepion Pharmaceuticals is at the forefront of developing treatments for complex diseases like non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic conditions. The company uses Artificial Intelligence (AI) to drive its therapeutic drug development, which is a modern approach that could revolutionize treatment methodologies in the medical field. Promising Clinical Trial Results The company's lead drug, Rencofilstat, has shown promising results in the Phase 2 ALTITUDE-NASH clinical trial. This trial achieved primary and secondary endpoints, including improvement in liver function and multiple NASH biomarkers. Additionally, Hepion Pharmaceuticals announced major reductions in liver stiffness with Rencofilstat treatment in a 17-week Phase 2 study of advanced MASH liver disease. These positive outcomes from clinical trials are strong indicators of the drug's potential efficacy and success.
Be patient. keep waiting for 2 USD... it will keep going down with fake upward spikes
Let's think about it.. When they declared a split the price was 0.7 USD. They needed to hold a 1 USD level to stay in NASDAQ, they needed a +50% growth. They realized that they were not capable of that, which shows that they were aware that their future releases and updates were not going to be sufficient to attrack new investors. Therefore they use a split.. Because of this investors sold their shares and the price fell from 0.7 to 0.5. Then, after the split, it kept falling from 10 to 6, so the real value became 0.3 USD (a disaster). Once real investors sold, insiders and fishy traders decided to buy back the shares up to 20 USD...that is, up to the actual value of 1USD. Because of this alarming price without real suppor for it, now insiders are getting rid of these overvalued stocks selling them to newcomers who think that this is a growing company. Today the price is at 16 USD, that is, around 0.7 USD again. Would they buy more? No way, is an inflated stock, nobody wants to buy an inflated stock without a solid future... Thanks to this move we already know that a good entry point is 6 USD, but due to global consequences it must drop to 2 USD... 2 USD is a good starting point to reset this company from scratch..so until then let's wait
Dont buy this... now is at 10 USD after a split 1:20.. real value is 0.5 USD. It will never jump back to 20 USD, HEPA is meant to go back to 2 USD in the future, you will waste money here :D. Every company that splits to remain in NASDAQ fails to increase. of course in the short term it may jump back to 12 or even 15 but the ultimate value in this season is 2 USD... so a total waste....
Split reflects that they don't have money nor good results in the coming months to reach the 0.1USD threshold... In simple terms "they suc$k". Sell their trash. Come back when they are back to 2USD...downtrend is so
hepion's comeback
any reason?
they got a nofitication to reach the minium value of 1USD..otherwise they are out of NASDAQ. so they will try to remain above 1... you can read all on their website
1.05 is quite delicious :)
Why is it showing 0.627? This stock closed at 1.59.
Another offering up for vote, bad news
Hepion was supposed to release treatment results in February and they never did. I suggest to newcomers...don't invest here. They lost credibility by missing deadlines. Moreover, investors bought at 2.00 and they are losing. Just wait for news to come in its website then you are welcome to come. Daytraders are likely winning because the oscillations here are so rewarding if you focus on profiting from the continous downtrend, don't wait for miracles in the long term until you have solid news. Cheers
Be ready to buy at 1 USD :D....enjoy the ride
Poor private company that bought shares at 2.00. They must be regreting. Now I buy at a lower price :). 1.7 is quite delicious. even if it drops to 1 due to the global crisis...is an amazing value for the long run...
This comment didn't age well..
I like the stock!
Why -20% in Pre Market?
Buying oppurtinity now, after the offering
Wow... Big Red... Cinnamon.
Anyone around?
Nice volume, though.
As mentioned nash results were given end of December and the company soared..but they are just preliminary results. second jump likely end of January or beginning of February. congrats
if you miss it you are not late. hepion grows due to covid treatment but the major jump will be nash in January..
unluckily don't buy this yet.. wait for 1.2 at least.
good buy. due to new shares given minimal is 1.5 now.
 what is the forecast?
at this level I suggest to trade with the oscillations. between 1.5-1.6 is solid buy. above those numbers... enjoy the oscillations. by january nash treatment results must be available (if not end of December)......for now it will oscillate between 1.5-2.0
hepa did a good job. thanks. I will come back after earnings. now nothing solid to show. big party in november
well game over for now. sell 75% and wait for a miracle with a 25%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.